These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15625049)

  • 21. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The story of drotrecogin alfa - evidence-based or evidence-biased?
    Wiseman R; Blockman M
    S Afr Med J; 2011 Dec; 102(1):8. PubMed ID: 22273122
    [No Abstract]   [Full Text] [Related]  

  • 24. Management of sepsis in the critically ill patient: key aspects.
    Vincent JL
    Expert Opin Pharmacother; 2006 Oct; 7(15):2037-45. PubMed ID: 17020431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
    Hjelmgren J; Persson U; Tennvall GR
    Am J Ther; 2005; 12(5):425-30. PubMed ID: 16148428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach.
    Riou França L; Payet S; Le Lay K; Launois R
    Value Health; 2008 Dec; 11(7):1051-60. PubMed ID: 18494757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
    Barie PS
    Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
    [No Abstract]   [Full Text] [Related]  

  • 28. After Xigris, researchers look to new targets to combat sepsis.
    Williams SC
    Nat Med; 2012 Jul; 18(7):1001. PubMed ID: 22772543
    [No Abstract]   [Full Text] [Related]  

  • 29. Should health care money in South Africa be spent on drotrecogin alfa?
    Taylor B; Burns D; van de Wal BW; MBewu T; Keeton GR
    S Afr Med J; 2003 Jul; 93(7):500-1. PubMed ID: 12939917
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacist intervention in activated protein C therapy for severe sepsis: influence on health and economic outcomes.
    Chan AL; Hsieh HJ; Lin SJ
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):229-35. PubMed ID: 19356388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
    Riou França L; Launois R; Le Lay K; Aegerter P; Bouhassira M; Meshaka P; Guidet B
    Int J Technol Assess Health Care; 2006; 22(1):101-8. PubMed ID: 16673686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicare to partly cover extra cost of sepsis therapy, drug-eluting stents.
    Thompson CA
    Am J Health Syst Pharm; 2002 Oct; 59(19):1816-7. PubMed ID: 12374063
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe sepsis management are we doing enough?
    Ahrens T; Vollman K
    Crit Care Nurse; 2003 Oct; 23(5 Suppl):2-15; quiz 17. PubMed ID: 14619742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Kalenka A
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698-9; author reply 1699-70. PubMed ID: 15273924
    [No Abstract]   [Full Text] [Related]  

  • 37. The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C.
    Doig CJ; Laupland KB; Zygun DA; Manns BJ
    Expert Opin Pharmacother; 2003 Oct; 4(10):1789-99. PubMed ID: 14521488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The economic burden of sepsis in Austria.
    Schmid A; Schneider H
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
    [No Abstract]   [Full Text] [Related]  

  • 39. An economic evaluation of activated protein C treatment for severe sepsis.
    Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
    N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Activated protein C, coagulation, inflammation and treatment of severe sepsis].
    Ott A
    Ned Tijdschr Geneeskd; 2001 Nov; 145(45):2196-7. PubMed ID: 11727624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.